Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans

Increased Hepatic Synthesis and Dysregulation of Cholesterol Metabolism Is Associated with the Severity of Nonalcoholic Fatty Liver Disease

(2012) Hae-Ki Min et al.   Cell Metabolism

Chronic treatment with a glucokinase activator delays the onset of hyperglycaemia and preserves beta cell mass in the Zucker diabetic fatty rat

(2012) M. Futamura et al.   DIABETOLOGIA

Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes

(2011) G. E. Meininger et al.   DIABETES CARE

Chronic glucokinase activation reduces glycaemia and improves glucose tolerance in high-fat diet fed mice

(2011) Maria Sörhede Winzell et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents

(2011) Nicola Santoro et al.   HEPATOLOGY

Hepatic Glucokinase Expression Is Associated with Lipogenesis and Fatty Liver in Humans

(2011) Andreas Peter et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Type 2 diabetes across generations: from pathophysiology to prevention and management

(2011) Christopher J Nolan et al.   LANCET

Systematic review of performance of non-invasive biomarkers in the evaluation of non-alcoholic fatty liver disease

(2011) Michael H. Miller et al.   LIVER INTERNATIONAL

Pharmacokinetic and Pharmacodynamic Properties of the Glucokinase Activator MK-0941 in Rodent Models of Type 2 Diabetes and Healthy Dogs

(2011) J.-i. Eiki et al.   MOLECULAR PHARMACOLOGY

Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment

(2011) Briohny W. Smith et al.   Nature Reviews Endocrinology

Human Fatty Liver Disease: Old Questions and New Insights

(2011) J. C. Cohen et al.   SCIENCE

Recent advances in imaging hepatic fibrosis and steatosis

(2011) Kayur D Patel et al.   Expert Review of Gastroenterology & Hepatology

Guidelines for reporting experiments involving animals: the ARRIVE guidelines

(2010) JC McGrath et al.   BRITISH JOURNAL OF PHARMACOLOGY

Animal research: Reporting in vivo experiments: The ARRIVE guidelines

(2010) Carol Kilkenny et al.   BRITISH JOURNAL OF PHARMACOLOGY

Novel glucokinase activators: a patent review (2008 – 2010)

(2010) Ramakanth Sarabu et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Lipid-induced insulin resistance: unravelling the mechanism

(2010) Varman T Samuel et al.   LANCET

Association of rs780094 in GCKR with Metabolic Traits and Incident Diabetes and Cardiovascular Disease: The ARIC Study

(2010) Mark Bi et al.   PLoS One

The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver

(2009) Nicola L. Beer et al.   HUMAN MOLECULAR GENETICS

Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia

(2009) Kara K. Osbak et al.   HUMAN MUTATION

Investigation of Functionally Liver Selective Glucokinase Activators for the Treatment of Type 2 Diabetes

(2009) Gregory R. Bebernitz et al.   JOURNAL OF MEDICINAL CHEMISTRY

Hepatic Fatty Acid Composition Differs between Chronic Hepatitis C Patients with and without Steatosis

(2009) Bianca M. Arendt et al.   JOURNAL OF NUTRITION

Assessing the potential of glucokinase activators in diabetes therapy

(2009) Franz M. Matschinsky   NATURE REVIEWS DRUG DISCOVERY

Targeting Hepatic Glucokinase in Type 2 Diabetes: Weighing the Benefits and Risks

(2008) L. Agius   DIABETES

Hepatic Stearoyl-CoA Desaturase (SCD)-1 Activity and Diacylglycerol but Not Ceramide Concentrations Are Increased in the Nonalcoholic Human Fatty Liver

(2008) A. Kotronen et al.   DIABETES

Common Missense Variant in the Glucokinase Regulatory Protein Gene Is Associated With Increased Plasma Triglyceride and C-Reactive Protein but Lower Fasting Glucose Concentrations

(2008) M. Orho-Melander et al.   DIABETES

Causes and Metabolic Consequences of Fatty Liver

(2008) Norbert Stefan et al.   ENDOCRINE REVIEWS

Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice

(2008) Catherine Postic et al.   JOURNAL OF CLINICAL INVESTIGATION

SAR, Pharmacokinetics, Safety, and Efficacy of Glucokinase Activating 2-(4-Sulfonylphenyl)-N-thiazol-2-ylacetamides: Discovery of PSN-GK1

(2008) Lisa S. Bertram et al.   JOURNAL OF MEDICINAL CHEMISTRY

Newly identified loci that influence lipid concentrations and risk of coronary artery disease

(2008) Cristen J Willer et al.   NATURE GENETICS